Marengo Asia Hospitals is preparing to raise around ₹500 crore by selling a 10% stake, aiming for an overall valuation of ₹5,000 crore. The fundraising effort is backed by existing investors, including Samara Capital, the Godrej family office, and the Havells promoter family office.
The hospital chain reported revenues of approximately ₹1,200 crore for FY25–26. At the proposed valuation, this translates to a price-to-sales multiple of about 4.17x. To manage the deal and bring in new investors—particularly sovereign funds and healthcare-focused backers—the company has engaged Avendus Capital.
Since October 2020, Marengo has expanded rapidly through acquisitions, following a consolidation-driven model. The network now includes eight hospitals with a combined capacity of roughly 2,500 beds across the National Capital Region, Gujarat, and Rajasthan.
Beyond India, Marengo has entered Saudi Arabia, tapping into a healthcare market undergoing rapid transformation under Vision 2030. The country’s healthcare sector, valued at nearly $67 billion in 2024, is targeting 65% private participation by 2030 and is expected to require around 27,000 additional hospital beds.
The company is also exploring further acquisitions in Rajasthan and Maharashtra as it strengthens its domestic footprint and evaluates international opportunities.
India’s healthcare industry has witnessed a surge in investor interest, with hospitals attracting close to ₹43,310 crore in private equity investments between 2022 and 2024. Listed players such as Apollo Hospitals, Max Healthcare, and Fortis Healthcare command premium valuations, trading at P/E multiples ranging from around 59x to 68x.
These larger hospital chains typically operate at enterprise value-to-EBITDA multiples of 30–35x. Compared to them, Marengo’s targeted valuation appears ambitious given its current revenue base, though investors often place a premium on scalable, consolidation-led platforms.
The proposed valuation has drawn attention due to limited visibility on profitability metrics such as EBITDA margins. Without this data, benchmarking against listed peers becomes challenging.
Marengo’s acquisition-led strategy, while enabling rapid expansion, also introduces operational risks. Integrating multiple facilities can lead to inconsistencies in service quality and efficiency, which may affect occupancy and margins.
Its presence in Saudi Arabia offers strong growth potential but also exposes the company to regulatory and geopolitical uncertainties. Meanwhile, the Indian healthcare sector continues to face policy risks, including possible price controls on medical procedures and devices.
The fresh capital is expected to support Marengo’s next phase of expansion, particularly through acquisitions in key states and potential international scaling. India’s healthcare market is projected to grow at a CAGR of around 12% over the next three to five years, driven by increasing insurance penetration, rising incomes, and a growing burden of chronic diseases.
However, challenges such as regulatory complexity and the risk of oversupply in certain regions remain.
Marengo Asia Hospitals stands at a crucial growth juncture, balancing aggressive expansion with the need for operational stability. While its valuation ambitions reflect confidence in its scalable model, long-term success will depend on effective integration, consistent quality, and the ability to convert growth into sustainable profitability in an increasingly competitive healthcare landscape.
(Photo courtesy: marengoasiahospitals.com)